Cellceutix Obtains Initial Funding To Advance Its Head And Neck Cancer Drug
Cancer and anti-inflammatory drug developer Cellceutix (OTCBB: CTIX) completed a $400,000 9% Secured Convertible Debenture financing. The Debentures and concomitant interest come due December 1, 2009 and are convertible into the Company’s common stock at $1.50 a share.
More: continued here
Filed under: Ear, Nose and Throat on May 22nd, 2008